Hydroxyurea in essential thrombocythemia

Rate and clinical relevance of responses by European LeukemiaNet criteria

Alessandra Carobbio, Guido Finazzi, Elisabetta Antonioli, Alessandro M. Vannucchi, Giovanni Barosi, Marco Ruggeri, Francesco Rodeghiero, Federica Delaini, Alessandro Rambaldi, Tiziano Barbui

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

A definition of response by cytoreductive therapy in essential thrombocythemia was recently provided by the European LeukemiaNet (ELN). Complete, partial, or no clinicohematologic responses were defined on the bases of platelet count, disease-related symptoms, spleen size, and white blood cell count. To provide estimates and clinical correlation of responses according to these criteria, we retrospectively examined 416 essential thrombocythemia patients treated with hydroxyurea for at least 12 months. Complete response, partial response, and no response were 25%, 58%, and 17%, respectively. Age more than 60 years and JAK2V617F mutation were significant predictors of response. After a median follow-up of 3.9 years, we registered 23 deaths, 16 hematologic transformations, and 27 thrombotic events (rate, 1.66% patients/year). Age, previous thrombosis, leukocytosis (white blood cell count > 10 × 109/L), but not ELN responses, were independently associated with higher risk of thrombosis. The actuarial probability of thrombosis was significantly influenced by leukocytosis (P = .017) and not by platelet count, indicating that platelet number does not seem of prime relevance in the definition of ELN response.

Original languageEnglish
Pages (from-to)1051-1055
Number of pages5
JournalBlood
Volume116
Issue number7
DOIs
Publication statusPublished - Aug 19 2010

Fingerprint

Essential Thrombocythemia
Hydroxyurea
Platelets
Platelet Count
Thrombosis
Leukocytosis
Leukocyte Count
Blood
Cells
Spleen
Mutation
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology
  • Medicine(all)

Cite this

Carobbio, A., Finazzi, G., Antonioli, E., Vannucchi, A. M., Barosi, G., Ruggeri, M., ... Barbui, T. (2010). Hydroxyurea in essential thrombocythemia: Rate and clinical relevance of responses by European LeukemiaNet criteria. Blood, 116(7), 1051-1055. https://doi.org/10.1182/blood-2010-03-272179

Hydroxyurea in essential thrombocythemia : Rate and clinical relevance of responses by European LeukemiaNet criteria. / Carobbio, Alessandra; Finazzi, Guido; Antonioli, Elisabetta; Vannucchi, Alessandro M.; Barosi, Giovanni; Ruggeri, Marco; Rodeghiero, Francesco; Delaini, Federica; Rambaldi, Alessandro; Barbui, Tiziano.

In: Blood, Vol. 116, No. 7, 19.08.2010, p. 1051-1055.

Research output: Contribution to journalArticle

Carobbio, A, Finazzi, G, Antonioli, E, Vannucchi, AM, Barosi, G, Ruggeri, M, Rodeghiero, F, Delaini, F, Rambaldi, A & Barbui, T 2010, 'Hydroxyurea in essential thrombocythemia: Rate and clinical relevance of responses by European LeukemiaNet criteria', Blood, vol. 116, no. 7, pp. 1051-1055. https://doi.org/10.1182/blood-2010-03-272179
Carobbio A, Finazzi G, Antonioli E, Vannucchi AM, Barosi G, Ruggeri M et al. Hydroxyurea in essential thrombocythemia: Rate and clinical relevance of responses by European LeukemiaNet criteria. Blood. 2010 Aug 19;116(7):1051-1055. https://doi.org/10.1182/blood-2010-03-272179
Carobbio, Alessandra ; Finazzi, Guido ; Antonioli, Elisabetta ; Vannucchi, Alessandro M. ; Barosi, Giovanni ; Ruggeri, Marco ; Rodeghiero, Francesco ; Delaini, Federica ; Rambaldi, Alessandro ; Barbui, Tiziano. / Hydroxyurea in essential thrombocythemia : Rate and clinical relevance of responses by European LeukemiaNet criteria. In: Blood. 2010 ; Vol. 116, No. 7. pp. 1051-1055.
@article{2ef20336314340d3b27581d79eb813b4,
title = "Hydroxyurea in essential thrombocythemia: Rate and clinical relevance of responses by European LeukemiaNet criteria",
abstract = "A definition of response by cytoreductive therapy in essential thrombocythemia was recently provided by the European LeukemiaNet (ELN). Complete, partial, or no clinicohematologic responses were defined on the bases of platelet count, disease-related symptoms, spleen size, and white blood cell count. To provide estimates and clinical correlation of responses according to these criteria, we retrospectively examined 416 essential thrombocythemia patients treated with hydroxyurea for at least 12 months. Complete response, partial response, and no response were 25{\%}, 58{\%}, and 17{\%}, respectively. Age more than 60 years and JAK2V617F mutation were significant predictors of response. After a median follow-up of 3.9 years, we registered 23 deaths, 16 hematologic transformations, and 27 thrombotic events (rate, 1.66{\%} patients/year). Age, previous thrombosis, leukocytosis (white blood cell count > 10 × 109/L), but not ELN responses, were independently associated with higher risk of thrombosis. The actuarial probability of thrombosis was significantly influenced by leukocytosis (P = .017) and not by platelet count, indicating that platelet number does not seem of prime relevance in the definition of ELN response.",
author = "Alessandra Carobbio and Guido Finazzi and Elisabetta Antonioli and Vannucchi, {Alessandro M.} and Giovanni Barosi and Marco Ruggeri and Francesco Rodeghiero and Federica Delaini and Alessandro Rambaldi and Tiziano Barbui",
year = "2010",
month = "8",
day = "19",
doi = "10.1182/blood-2010-03-272179",
language = "English",
volume = "116",
pages = "1051--1055",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - Hydroxyurea in essential thrombocythemia

T2 - Rate and clinical relevance of responses by European LeukemiaNet criteria

AU - Carobbio, Alessandra

AU - Finazzi, Guido

AU - Antonioli, Elisabetta

AU - Vannucchi, Alessandro M.

AU - Barosi, Giovanni

AU - Ruggeri, Marco

AU - Rodeghiero, Francesco

AU - Delaini, Federica

AU - Rambaldi, Alessandro

AU - Barbui, Tiziano

PY - 2010/8/19

Y1 - 2010/8/19

N2 - A definition of response by cytoreductive therapy in essential thrombocythemia was recently provided by the European LeukemiaNet (ELN). Complete, partial, or no clinicohematologic responses were defined on the bases of platelet count, disease-related symptoms, spleen size, and white blood cell count. To provide estimates and clinical correlation of responses according to these criteria, we retrospectively examined 416 essential thrombocythemia patients treated with hydroxyurea for at least 12 months. Complete response, partial response, and no response were 25%, 58%, and 17%, respectively. Age more than 60 years and JAK2V617F mutation were significant predictors of response. After a median follow-up of 3.9 years, we registered 23 deaths, 16 hematologic transformations, and 27 thrombotic events (rate, 1.66% patients/year). Age, previous thrombosis, leukocytosis (white blood cell count > 10 × 109/L), but not ELN responses, were independently associated with higher risk of thrombosis. The actuarial probability of thrombosis was significantly influenced by leukocytosis (P = .017) and not by platelet count, indicating that platelet number does not seem of prime relevance in the definition of ELN response.

AB - A definition of response by cytoreductive therapy in essential thrombocythemia was recently provided by the European LeukemiaNet (ELN). Complete, partial, or no clinicohematologic responses were defined on the bases of platelet count, disease-related symptoms, spleen size, and white blood cell count. To provide estimates and clinical correlation of responses according to these criteria, we retrospectively examined 416 essential thrombocythemia patients treated with hydroxyurea for at least 12 months. Complete response, partial response, and no response were 25%, 58%, and 17%, respectively. Age more than 60 years and JAK2V617F mutation were significant predictors of response. After a median follow-up of 3.9 years, we registered 23 deaths, 16 hematologic transformations, and 27 thrombotic events (rate, 1.66% patients/year). Age, previous thrombosis, leukocytosis (white blood cell count > 10 × 109/L), but not ELN responses, were independently associated with higher risk of thrombosis. The actuarial probability of thrombosis was significantly influenced by leukocytosis (P = .017) and not by platelet count, indicating that platelet number does not seem of prime relevance in the definition of ELN response.

UR - http://www.scopus.com/inward/record.url?scp=77956553291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956553291&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-03-272179

DO - 10.1182/blood-2010-03-272179

M3 - Article

VL - 116

SP - 1051

EP - 1055

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -